Featured Research

from universities, journals, and other organizations

HIV Domains Take On New Functions In Mediating Immunity

Date:
July 9, 2005
Source:
Journal of Clinical Investigation
Summary:
HIV evades the host immune system to cause infection. In a JCI study researchers examine the fusion peptide (FP) of HIV and show it plays two roles in HIV infection -- it mediates fusion of the virus with the cell membrane, while also downregulating the T cell responses that normally block infection. The authors show that FP ameliorates the autoimmune disease adjuvant arthritis in rats. This study shows that FP, independent of HIV, may provide a novel way to decrease undesirable immune responses.

HIV is able to evade the host immune system to cause infection. In particular, HIV downregulates CD4+ immune T cell function, which might aid infection, but the mechanisms underlying this phenomenon are unknown. In a study appearing online on July 7 in advance of print publication of the August 1 issue of the Journal of Clinical Investigation, Yechiel Shai and colleagues from the Weizmann Institute examine the fusion peptide (FP) of HIV.

The researchers show that the FP plays two roles in HIV infection – it works with other domains to mediate fusion of the virus with the cell membrane, while also downregulating the T cell responses that normally would block infection.

The authors show that the HIV FP can co-localize with CD4 and T cell receptor in T cells, and inhibits antigen-specific T cell proliferation. This data highlights a potential immunosuppressive activity specific to HIV infection.

The authors then extend their findings by exploiting the activity of FP and show that it ameliorates the autoimmune disease adjuvant arthritis in rats. This study not only adds to our understanding of the mechanisms of HIV pathogenesis, but it also shows that the FP molecule, independent of HIV, may provide a novel way to decrease undesirable immune responses.

###

Title: HIV-1 Fusion Peptide Targets the TCR and Inhibits Antigen-Specific T-Cell Activation


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "HIV Domains Take On New Functions In Mediating Immunity." ScienceDaily. ScienceDaily, 9 July 2005. <www.sciencedaily.com/releases/2005/07/050709002120.htm>.
Journal of Clinical Investigation. (2005, July 9). HIV Domains Take On New Functions In Mediating Immunity. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/07/050709002120.htm
Journal of Clinical Investigation. "HIV Domains Take On New Functions In Mediating Immunity." ScienceDaily. www.sciencedaily.com/releases/2005/07/050709002120.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins